Resveratrol — Research Profile

No. Red wine contains only 1-2mg resveratrol per glass. To reach a supplemental dose of 250mg, you would need to drink 125-250 glasses daily, which is obviously impractical and harmful. Supplements provide concentrated trans-resveratrol at therapeutic doses that are impossible to achieve through diet alone.

Many longevity researchers, including David Sinclair, combine resveratrol with NMN based on the rationale that SIRT1 (activated by resveratrol) requires NAD+ (boosted by NMN) as a cofactor. The combination may be synergistic — resveratrol accelerates the enzyme, while NMN provides the fuel. However, this combination has not been tested in controlled human trials.

Less than 1% of oral resveratrol reaches the bloodstream unchanged due to rapid metabolism in the gut and liver (glucuronidation and sulfation). However, resveratrol metabolites may retain biological activity. Taking resveratrol with fat, choosing micronized or liposomal forms, and pairing with piperine (black pepper extract) can improve absorption.

Trans-resveratrol is the form to look for: the trans isomer is the dominant, more chemically stable configuration and the one credited with resveratrol's bioactivity, and it is the version dosed in human trials. Because plain resveratrol is poorly absorbed and rapidly metabolized, the practical lever is formulation: a micronized microparticle preparation reached plasma concentrations roughly 3.6-fold higher than an equivalent dose of ordinary resveratrol. No single branded delivery form, however, has been proven to convert that higher exposure into better clinical outcomes.

Despite roughly 200 clinical trials across more than 24 conditions, a 2024 systematic review concluded there is no conclusive clinical evidence to recommend resveratrol in any healthcare setting. What it does show fairly consistently is reduced inflammatory markers and improvement in some aspects of dysregulated metabolism; in women with PCOS, meta-analysis found significant reductions in testosterone, luteinizing hormone and DHEAS. Notably, in post-menopausal women it produced no significant change in total, LDL, or HDL cholesterol or triglycerides, so benefits are outcome- and population-specific rather than broad.

No standardized dose is established because no clinical benefit is firmly proven. Trials have used anywhere from 5 mg to 5 g/day; metabolic effects were seen at just 150 mg/day, while a common over-the-counter regimen is 500 mg twice daily. Staying at or below about 1 g/day keeps you within the range that is generally well tolerated, since higher intakes mainly add gastrointestinal side effects rather than clearer benefit.

The best time of day has not been directly tested in resveratrol trials, which have simply dosed it once or twice daily without comparing morning versus evening. Because absorption depends heavily on formulation and is affected by food, taking it consistently with a meal is a reasonable practical choice, but no timing has been shown to improve outcomes. Multi-gram single doses are more likely to cause loose stools, which some people manage by splitting the dose.

At doses under 1 g/day resveratrol causes little or no drug-related adverse effect. The main side effects are gastrointestinal and dose-dependent: nausea, flatulence, abdominal pain and diarrhea, which appear more often above roughly 0.5 g/day and become common at multi-gram intakes. Milder reports include headache and fatigue, and a case of contact dermatitis was linked to a topical resveratrol cream rather than an oral supplement.

Yes. At 1 g/day for 4 weeks resveratrol inhibited the drug-metabolizing enzymes CYP3A4, 2D6 and 2C9 and induced CYP1A2 in healthy volunteers, which can raise blood levels of medications cleared by those pathways; a resveratrol-rich supplement has been reported to increase carbamazepine levels. It also inhibits platelet aggregation, so combining it with warfarin or antiplatelet drugs may increase bleeding risk. Its estrogen-like activity is a further reason for caution with hormonal therapies and hormone-sensitive conditions.

No group has conclusive evidence that resveratrol will help them, so it is best viewed as investigational rather than indicated. The most-studied populations are people with metabolic and cardiovascular conditions, type 2 diabetes, and PCOS, where it has shown modest hormonal or inflammatory changes but not proven clinical benefit. It should be avoided or used only under medical supervision by people on blood thinners, those with hormone-sensitive cancers, and during pregnancy, given its antiplatelet and estrogen-like activity.

There is no defined onset because resveratrol has no proven clinical endpoint to time. In the most-cited human study, 150 mg/day of trans-resveratrol shifted metabolic markers (SIRT1, AMPK, resting metabolic rate, systolic blood pressure, glucose) over a 30-day crossover in obese men. Most other trials ran 4 weeks to 12 months, so any metabolic or inflammatory change would emerge over weeks rather than days, and results vary sharply by dose and formulation.

Resveratrol has a reassuring liver-safety record: NIH LiverTox rates it an unlikely cause of clinically apparent liver injury (likelihood score E), with no published cases despite widespread use. Clinical trials have dosed it for up to about 52 weeks, generally without serious adverse events at doses up to roughly 1 g/day. Safety beyond one year and at multi-gram doses has not been well characterized, so open-ended high-dose use is not backed by long-term data.

Yes. No formal upper limit exists, but the tolerability ceiling is gastrointestinal: doses under 1 g/day cause little or no adverse effect, while amounts above roughly 0.5-1 g/day produce nausea, flatulence, abdominal cramps and diarrhea, which become frequent at multi-gram doses. Human trials have gone as high as 5 g/day, and at those levels loose stools and nausea are common rather than exceptional.

No supplement pairing with resveratrol has been validated for added benefit in human trials, so combining is a matter of caution rather than proven synergy. The relevant risk is that resveratrol inhibits platelet aggregation and the CYP3A4, 2D6 and 2C9 enzymes, so stacking it with other supplements that thin the blood (fish oil, high-dose vitamin E, ginkgo) or that share those liver pathways could compound those effects. There is no reliable evidence that co-supplements improve its poor absorption.

Look for a product standardized to trans-resveratrol: the trans isomer is the dominant, more stable form and is the one to which resveratrol's biological activity is attributed, and it is the version used in clinical trials. Commercial resveratrol is commonly extracted from Japanese knotweed (Polygonum cuspidatum), a resveratrol-rich plant long used in traditional medicine, so check that the label states an actual trans-resveratrol amount rather than a vague proprietary blend. Because oral bioavailability is inherently poor, formulation matters: a micronized microparticle preparation reached plasma levels about 3.6-fold higher than an equivalent dose of ordinary resveratrol.